METIS TECHBIO-P Surges Over 10% Intraday, Secures $1.1 Billion Lilly AI-LNP Deal

Deep News10-21

Hot topics | Watchlist | Data center | Market center | Capital flows | Simulated trading client. METIS TECHBIO-P (07666) surged more than 10% intraday. As of press time, the stock was up 2.41% at HK$11.46, with turnover of HK$84.131 million.

On October 19, METIS TECHBIO-P entered into a collaboration with globally renowned multinational pharmaceutical company Eli Lilly on the world's largest AI-driven extrahepatic LNP delivery platform deal by total transaction value, which also marks China's first generative AI-LNP platform strategic collaboration.

Under this landmark strategic partnership, valued at up to US$1.1 billion, the two parties will focus on the research and discovery of novel LNP (lipid nanoparticle) delivery solutions, aiming to explore tissue-specific delivery solutions that support multiple therapeutic modalities.

As METIS TECHBIO's self-developed AI nanodelivery platform, NanoForge employs a proprietary integrated innovation framework combining "dry lab + wet lab + intelligent agents," and has achieved a complete chain covering AI protein generation, in vivo delivery technology, and next-generation immunotherapy development.

In recent years, the NanoForge platform, a key Biological AI infrastructure independently developed by METIS TECHBIO, has gained broad recognition from international professional investment institutions and leading multinational pharmaceutical companies. The major strategic collaboration with Eli Lilly clearly once again validates NanoForge's strong capability to continuously generate globally valuable innovative assets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179010962?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-21 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179010962","market":"nz","top_or_hot":-1,"title":"METIS TECHBIO-P Surges Over 10% Intraday, Secures $1.1 Billion Lilly AI-LNP Deal","media":"Deep News","content":"<p>Hot topics | Watchlist | Data center | Market center | Capital flows | Simulated trading client. <b>METIS TECHBIO-P</b> (<b>07666</b>) surged more than 10% intraday. As of press time, the stock was up 2.41% at HK$11.46, with turnover of HK$84.131 million.<br><br>On October 19, <b>METIS TECHBIO-P</b> entered into a collaboration with globally renowned multinational pharmaceutical company <b>Eli Lilly</b> on the world's largest AI-driven extrahepatic LNP delivery platform deal by total transaction value, which also marks China's first generative AI-LNP platform strategic collaboration.<br><br>Under this landmark strategic partnership, valued at up to US$1.1 billion, the two parties will focus on the research and discovery of novel LNP (lipid nanoparticle) delivery solutions, aiming to explore tissue-specific delivery solutions that support multiple therapeutic modalities.<br><br>As <b>METIS TECHBIO</b>'s self-developed AI nanodelivery platform, NanoForge employs a proprietary integrated innovation framework combining \"dry lab + wet lab + intelligent agents,\" and has achieved a complete chain covering AI protein generation, in vivo delivery technology, and next-generation immunotherapy development.<br><br>In recent years, the NanoForge platform, a key Biological AI infrastructure independently developed by <b>METIS TECHBIO</b>, has gained broad recognition from international professional investment institutions and leading multinational pharmaceutical companies. The major strategic collaboration with <b>Eli Lilly</b> clearly once again validates NanoForge's strong capability to continuously generate globally valuable innovative assets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>METIS TECHBIO-P Surges Over 10% Intraday, Secures $1.1 Billion Lilly AI-LNP Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMETIS TECHBIO-P Surges Over 10% Intraday, Secures $1.1 Billion Lilly AI-LNP Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-10-21 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hot topics | Watchlist | Data center | Market center | Capital flows | Simulated trading client. <b>METIS TECHBIO-P</b> (<b>07666</b>) surged more than 10% intraday. As of press time, the stock was up 2.41% at HK$11.46, with turnover of HK$84.131 million.<br><br>On October 19, <b>METIS TECHBIO-P</b> entered into a collaboration with globally renowned multinational pharmaceutical company <b>Eli Lilly</b> on the world's largest AI-driven extrahepatic LNP delivery platform deal by total transaction value, which also marks China's first generative AI-LNP platform strategic collaboration.<br><br>Under this landmark strategic partnership, valued at up to US$1.1 billion, the two parties will focus on the research and discovery of novel LNP (lipid nanoparticle) delivery solutions, aiming to explore tissue-specific delivery solutions that support multiple therapeutic modalities.<br><br>As <b>METIS TECHBIO</b>'s self-developed AI nanodelivery platform, NanoForge employs a proprietary integrated innovation framework combining \"dry lab + wet lab + intelligent agents,\" and has achieved a complete chain covering AI protein generation, in vivo delivery technology, and next-generation immunotherapy development.<br><br>In recent years, the NanoForge platform, a key Biological AI infrastructure independently developed by <b>METIS TECHBIO</b>, has gained broad recognition from international professional investment institutions and leading multinational pharmaceutical companies. The major strategic collaboration with <b>Eli Lilly</b> clearly once again validates NanoForge's strong capability to continuously generate globally valuable innovative assets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTHR","symbol_name":"Vanguard Russell 3000 ETF","start_time":0,"source_url":"","article_id":"1179010962","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179010962","pubTimestamp":1792555236,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Hot topics | Watchlist | Data center | Market center | Capital flows | Simulated trading client. METIS TECHBIO-P (07666) surged more than 10% intraday. As of press time, the stock was up 2.41% at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTHR":"Vanguard Russell 3000 ETF","AIPO":"Defiance AI and Power Infrastructure ETF","07666":"剂泰科技-P","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","AGIX":"通用人工智能 ETF-AGIX","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","QTOC":"Innovator Growth Accelerated Plus ETF - October"},"translate_title":"METIS TECHBIO-P 盘中飙升超过 10%，获得 11 亿美元的礼来 AI-LNP 交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTOC":1,"ARTY":1,"AIPO":1,"AGIX":1,"07666":1,"VTHR":1,"CHAT":1},"content_text":"Hot topics | Watchlist | Data center | Market center | Capital flows | Simulated trading client. METIS TECHBIO-P (07666) surged more than 10% intraday. As of press time, the stock was up 2.41% at HK$11.46, with turnover of HK$84.131 million.On October 19, METIS TECHBIO-P entered into a collaboration with globally renowned multinational pharmaceutical company Eli Lilly on the world's largest AI-driven extrahepatic LNP delivery platform deal by total transaction value, which also marks China's first generative AI-LNP platform strategic collaboration.Under this landmark strategic partnership, valued at up to US$1.1 billion, the two parties will focus on the research and discovery of novel LNP (lipid nanoparticle) delivery solutions, aiming to explore tissue-specific delivery solutions that support multiple therapeutic modalities.As METIS TECHBIO's self-developed AI nanodelivery platform, NanoForge employs a proprietary integrated innovation framework combining \"dry lab + wet lab + intelligent agents,\" and has achieved a complete chain covering AI protein generation, in vivo delivery technology, and next-generation immunotherapy development.In recent years, the NanoForge platform, a key Biological AI infrastructure independently developed by METIS TECHBIO, has gained broad recognition from international professional investment institutions and leading multinational pharmaceutical companies. The major strategic collaboration with Eli Lilly clearly once again validates NanoForge's strong capability to continuously generate globally valuable innovative assets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179010962","isCrawlerRequest":true}